当前位置: X-MOL 学术BJU Int. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette–Guérin?
BJU International ( IF 4.5 ) Pub Date : 2021-12-01 , DOI: 10.1111/bju.15665
Niyati Lobo 1 , Patrick J Hensley 1 , Kelly K Bree 1 , Graciela M Nogueras-Gonzalez 2 , Neema Navai 1 , Colin P Dinney 1 , Ashish M Kamat 1
Affiliation  

To determine the impact of fibrin clot inhibitor (FCI) use on oncological outcomes in a large contemporary cohort of patients with non-muscle-invasive bladder cancer (NMIBC) treated with adequate bacille Calmette–Guérin (BCG).

中文翻译:

非肌层浸润性膀胱癌患者是否应在卡介苗期间停用纤维蛋白凝块抑制剂?

确定纤维蛋白凝块抑制剂 (FCI) 的使用对使用足量卡介苗 (BCG) 治疗的非肌肉浸润性膀胱癌 (NMIBC) 患者的大型当代队列的肿瘤学结果的影响。
更新日期:2021-12-01
down
wechat
bug